Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Year-to-date money raised in public, private and other financings of biopharma companies.

Follow-ons completed by biopharma companies, including: Adaptimmune, Albireo, Alector, Apellis, Applied, Aptinyx, Autolus, Biohaven, Blueprint Medicines, Catabasis, Concert, DBV, Denali, Heat Biologics, Hutchison China Meditech, Immunogen, Intelgenx, Intra-Cellular, Matinas, Mirati, Mirum, Nanoviricides, Osmotica, Trillium, Xenon, Zai Lab, Zymeworks.

Private placements and other private financings of public biopharma companies, including: Advaxis, Algernon, Alimera, Armata, Azurrx, Bergenbio, Biocurepharm Korea, Bonus Biogroup, Cellect, Chemocentryx, Cidara, Clovis, Cocrystal, Edesa, Epizyme, Eyegate, Genprex, Helix, Hemogenyx, Hemostemix, Infinity, Iterum, Kamada, Leap, Lineage Cell, Novus, Noxxon, Promis, Puretech, Saniona, Sellas, Seneca, Spero, Tetra, Tetraphase, Titan, Vaxil, Vitro, Wize.

Venture capital and other private financings of private biopharma companies, including: Adagene, Aegle, Agilvax, Airway, Alderaan, Aligos, Arpeggio, Biograil, Biointervene, Bionetix, Calidi, Cerebral, Codagenix, Domain, Empirico, Eqrx, Fusion, Genesen, Heparegenix, Idbydna, Immuneering, Jasper, Kyverna, Lyra, Nference, Northsea, Seekyo, Tarsus, Treadwell, Tscan, Tyra, Urania, Vectivbio.

Triggered milestone payments disclosed by biopharma companies, including: BMS, Evotec, Gilead, Newsoara, Roche, Scholar Rock, Seattle Genetics, Zenith Epigenetics.

These graphs compare the performance of the biotech stocks for all of 2019 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.